Related Experiment Video
Updated: Jul 1, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Decreased circulating CTRP3 levels in acute and chronic cardiovascular patients
Andreas Schmid1, Sabine Pankuweit2, Ann-Kathrin Vlacil2
1Department of Internal Medicine III, Giessen University Hospital, Giessen, Germany. andreas.schmid@innere.med.uni-giessen.de.
Insights
Circulating CTRP3 levels are decreased in male patients with chronic or acute coronary artery disease (CAD). Plasma CTRP3 shows potential as a biomarker for identifying male CAD patients but cannot differentiate acute from chronic conditions.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Biomarker Discovery
Background:
- C1q/TNF-related protein 3 (CTRP3) is an adipokine with metabolic and immune functions.
- Previous studies on CTRP3 as a cardiovascular disease (CVD) biomarker are contradictory.
- The role of CTRP3 in coronary artery disease (CAD) requires further investigation.
Purpose of the Study:
- To investigate CTRP3 levels in patients with chronic coronary syndrome (CCS) and acute coronary syndrome (ACS).
- To evaluate CTRP3 as a potential biomarker for differentiating CAD severity and acuity.
- To compare CTRP3 regulation in human patients with murine models of cardiovascular pathophysiology.
Main Methods:
- Recruitment of 206 patients with CCS, ACS (first or recurrent event), and 49 healthy controls.
- ELISA measurement of peripheral blood CTRP3 levels.
- Receiver Operating Characteristic (ROC) curve analysis to assess predictive value in male patients.
Main Results:
- CTRP3 levels were significantly decreased in male CCS and ACS patients compared to controls (p < 0.001).
- No significant difference in CTRP3 levels was observed between CCS, ACS-1, and ACS-2 patient groups.
- Plasma CTRP3 demonstrated predictive value for identifying male CAD patients (cut-off 51.25 ng/mL) with consistent sensitivity and specificity across subgroups.
- Female patients generally had higher CTRP3 levels than males.
- Murine models showed partly opposite CTRP3 regulation compared to human male findings.
Conclusions:
- Circulating CTRP3 levels are reduced in male patients with both chronic and acute coronary artery disease.
- Plasma CTRP3 serves as a potential biomarker for identifying male CAD patients.
- CTRP3 cannot distinguish between acute and chronic coronary artery disease settings.
Abstract:
C1q/TNF-related protein 3 (CTRP3) represents an adipokine with various metabolic and immune-regulatory functions. While circulating CTRP3 has been proposed as a potential biomarker for cardiovascular disease (CVD), current data on CTRP3 regarding coronary artery disease (CAD) remains partially contradictory. This study aimed to investigate CTRP3 levels in chronic and acute settings such as chronic coronary syndrome (CCS) and acute coronary syndrome (ACS). A total of 206 patients were classified into three groups: CCS (n = 64), ACS having a first acute event (ACS-1, n = 75), and ACS having a recurrent acute event (ACS-2, n = 67). The control group consisted of 49 healthy individuals. ELISA measurement in peripheral blood revealed decreased CTRP3 levels in all patient groups (p < 0.001) without significant differences between the groups. This effect was exclusively observed in male patients. Females generally exhibited significantly higher CTRP3 plasma levels than males. ROC curve analysis in male patients revealed a valuable predictive potency of plasma CTRP3 in order to identify CAD patients, with a proposed cut-off value of 51.25 ng/mL. The sensitivity and specificity of prediction by CTRP3 were congruent for the subgroups of CCS, ACS-1, and ACS-2 patients. Regulation of circulating CTRP3 levels in murine models of cardiovascular pathophysiology was found to be partly opposite to the clinical findings, with male mice exhibiting higher circulating CTRP3 levels than females. We conclude that circulating CTRP3 levels are decreased in both male CCS and ACS patients. Therefore, CTRP3 might be useful as a biomarker for CAD but not for distinguishing an acute from a chronic setting. KEY MESSAGES: CTRP3 levels were found to be decreased in both male CCS and ACS patients compared to healthy controls. Plasma CTRP3 has a valuable predictive potency in order to identify CAD patients among men and is therefore proposed as a biomarker for CAD but not for distinguishing between acute and chronic settings. Regulation of circulating CTRP3 levels in murine models of cardiovascular pathophysiology was found to be partly opposite to the clinical findings in men.
More Related Videos
07:40Impact of High-intensity Interval Exercise and Moderate-Intensity Continuous Exercise on the Cardiac Troponin T Level at an Early Stage of Training
Published on: October 10, 2019
07:59The Inverted Heart Model for Interstitial Transudate Collection from the Isolated Rat Heart
Published on: June 20, 2017
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...